Back to top
more

LeMaitre Vascular (LMAT)

(Delayed Data from NSDQ)

$101.71 USD

101.71
237,196

+3.08 (3.12%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $101.68 -0.03 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

MDT vs. LMAT: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

MDT vs. LMAT: Which Stock Is the Better Value Option?

LeMaitre Vascular (LMAT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SurModics (SRDX) Reports Break-Even Earnings for Q1

by Zacks Equity Research

SurModics (SRDX) delivered earnings and revenue surprises of 100% and 3.23%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

ESLOY or LMAT: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ESLOY vs. LMAT: Which Stock Is the Better Value Option?

How Much Upside is Left in LeMaitre (LMAT)? Wall Street Analysts Think 25.24%

by Zacks Equity Research

The consensus price target hints at a 25.2% upside potential for LeMaitre (LMAT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

PETQ or LMAT: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

PETQ vs. LMAT: Which Stock Is the Better Value Option?

Prestige Consumer (PBH) Stock Rallies 20% in a Year: Here's Why

by Zacks Equity Research

Prestige Consumer (PBH) benefits from a robust healthcare brand portfolio and solid demand.

Here's Why Investors Should Retain Acadia Healthcare (ACHC)

by Zacks Equity Research

Acadia Healthcare (ACHC) is well-poised for growth on the solid demand for behavioral healthcare services, the continuous pursuit of expansion initiatives and growing cash reserves.

Encompass Health (EHC) Up 41% in a Year: More Room for Growth?

by Zacks Equity Research

Encompass Health (EHC) is well-poised for growth on the back of growing revenues, an aging U.S. population, joint ventures and solid cash reserves.

Here's Why Investors Should Hold Humana (HUM) in Portfolio

by Zacks Equity Research

Humana (HUM) remains well-poised for growth on the back of an expanding Medicare Advantage membership, upgraded health plan offering suite and solid cash reserves.

Cigna (CI) Eases Care Delivery With Prior Authorization Removal

by Zacks Equity Research

Cigna's (CI) branch, Cigna Healthcare, lifts the prior authorization requirement on 600-plus medical services, thereby easing administrative burdens and making way for simplified care delivery.

Molina Healthcare (MOH) Wins Medicaid Deal From New Mexico HSD

by Zacks Equity Research

Molina Healthcare (MOH) receives a contract from the New Mexico HSD, subsequent to which it can effectively serve the statewide Medicaid members.

LeMaitre Vascular (LMAT) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

LeMaitre (LMAT) delivered earnings and revenue surprises of 15.63% and 3.78%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

ABT vs. LMAT: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

ABT vs. LMAT: Which Stock Is the Better Value Option?

Strength Seen in Zimmer (ZBH): Can Its 3.8% Jump Turn into More Strength?

by Zacks Equity Research

Zimmer (ZBH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

LeMaitre (LMAT) Upgraded to Strong Buy: Here's Why

by Zacks Equity Research

LeMaitre (LMAT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Best Momentum Stocks to Buy for May 23rd

by Zacks Equity Research

ONON, PKOH and LMAT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 23, 2023.

What Makes LeMaitre Vascular (LMAT) a Strong Momentum Stock: Buy Now?

by Zacks Equity Research

Does LeMaitre Vascular (LMAT) have what it takes to be a top stock pick for momentum investors? Let's find out.

LeMaitre Vascular (LMAT) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

LeMaitre (LMAT) delivered earnings and revenue surprises of 8% and 7.63%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ZBH or LMAT: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ZBH vs. LMAT: Which Stock Is the Better Value Option?

ZBH vs. LMAT: Which Stock Is the Better Value Option?

by Zacks Equity Research

ZBH vs. LMAT: Which Stock Is the Better Value Option?

LeMaitre Vascular (LMAT) Q4 Earnings and Revenues Lag Estimates

by Zacks Equity Research

LeMaitre (LMAT) delivered earnings and revenue surprises of -3.85% and 0.57%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

ZBH vs. LMAT: Which Stock Is the Better Value Option?

by Zacks Equity Research

ZBH vs. LMAT: Which Stock Is the Better Value Option?

Aurora Cannabis Inc. (ACB) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aurora Cannabis Inc. (ACB) delivered earnings and revenue surprises of -100% and 19.61%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

VREX vs. LMAT: Which Stock Is the Better Value Option?

by Zacks Equity Research

VREX vs. LMAT: Which Stock Is the Better Value Option?